Open Beta
MetriLume

US marketsAGIO

SEC-sourced researchBeta

AGIO

AGIOS PHARMACEUTICALS, INC.

Company comparison ↗

Data passport

CIK
0001439222
Exchange
Nasdaq
Business activity
Pharmaceutical Preparations · SIC 2834
Financial inputs
6/6
Filing date
Aug 6, 2026
SEC registry record
Operating company

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2023: 26,823,000.0000 USD; December 2024: 36,498,000.0000 USD; December 2025: 54,028,000.0000 USD54M USD0 USD0December 2023December 2024December 2025
AGIO · Exact amounts and source periods · USD
Period endRevenueFiling date
December 202326,823,000.0000Feb 12, 2026
December 202436,498,000.0000Feb 12, 2026
December 202554,028,000.0000Feb 12, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 202554,028,000.0000-412,781,000.0000-372,977,000.00001,297,225,000.0000104,111,000.0000Feb 12, 2026
December 202436,498,000.0000673,725,000.0000-389,841,000.00001,663,199,000.0000122,243,000.0000Feb 12, 2026
December 202326,823,000.0000-352,088,000.0000-296,062,000.0000——Feb 12, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

58/100
Profitability0
Growth98
Balance sheet92
Cash generation0
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$54.03MJan 1, 2025 – Dec 31, 2025Feb 12, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$36.5MJan 1, 2024 – Dec 31, 2024Feb 12, 202610-K
Net incomeNetIncomeLoss-$412.78MJan 1, 2025 – Dec 31, 2025Feb 12, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$372.98MJan 1, 2025 – Dec 31, 2025Feb 12, 202610-K
Total assetsAssets$1.3BDec 31, 2025Feb 12, 202610-K
Total liabilitiesLiabilities$104.11MDec 31, 2025Feb 12, 202610-K

New filings

Explore methodology ↗